• <code id="kgams"><tr id="kgams"></tr></code>
    <abbr id="kgams"></abbr>
  • <abbr id="kgams"></abbr>
    Home
    Who We Are
    What We Do
    Corporate Responsibility
    News
    Careers
    Investors
    Patients and HCPS
    Contact us
    Careers | Investors | Patients and HCPS | Contact us
    Careers Investors Patients and HCPS Contact us
    Home / Company News / Gan & Lee Pharmaceuticals Presents at American Diabetes Association's 83rd Scientific Sessions: Advancing Global Efforts in Diabetes Prevention and Control
    Gan & Lee Pharmaceuticals Presents at American Diabetes Association's 83rd Scientific Sessions: Advancing Global Efforts in Diabetes Prevention and Control
    Date:2023-06-28

    American Diabetes Association's 83rd Scientific Sessions recently concluded at the San Diego Conference Center in San Diego, California, USA, held from June 23-26, 2023. As one of the largest diabetes conferences globally, the conference drew over 12,000 esteemed physicians, scientists, and healthcare professionals from various parts of the world. This significant event showcased cutting-edge scientific breakthroughs in the diabetes field, encompassing more than 90 scientific sessions and featuring over 2,000 original research presentations1.


    Throughout the exhibition, Gan & Lee Pharmaceuticals' booth attracted experts, scholars, media representatives, doctors, and individuals associated with the diabetes field from various countries. This engagement helped enhance industry insiders' comprehension of Gan & Lee's current standing. One attendee expressed his delight, stating, "I am pleased to witness Gan & Lee's enduring dedication and profound commitment to the diabetes field. It is gratifying to see a Chinese company taking the stage at ADA to represent the voice of China.”


    In the medical information area, Gan & Lee's team prominently showcased the company's drug pipeline for the international market. The team also provided insights into the published clinical data that supports the company's Biologics License Application (BLA) at US FDA, thus laying a favorable and efficient groundwork for the subsequent launch of relevant products in the United States.


    Gan & Lee's insulin and device products have been launched in nearly 20 countries spanning four continents. Notably, this year, the company has received BLA acceptance from the U.S. FDA on its three core products – Insulin Glargine, Lispro, and Aspart. The three BLAs have entered the substantive review stage, and Gan & Lee will do their best to facilitate the approval in the U.S. and Europe. By actively expanding the product reach into diverse global markets, Gan & Lee strongly believes in fostering strong connections with the global diabetes community and extending the benefits of their products to a greater number of patients worldwide.


    References:

    1.American Diabetes Association. (2023, June 19). The American Diabetes Association commences its 83rd scientific sessions to showcase game changing diabetes advances. The American Diabetes Association Commences its 83rd Scientific Sessions to Showcase Game Changing Diabetes Advances | ADA. https://diabetes.org/newsroom/press-releases/2023/american-diabetes-association-commences-83rd-scientific-sessions-showcase-diabetes-advances


    About Gan & Lee

    Gan & Lee Pharmaceuticals has developed the first Chinese domestic biosynthetic human insulin. Currently, we have five recombinant insulin analogs commercialized in China including long-acting glargine injection (Basalin?), fast-acting lispro injection (Prandilin?), fast-acting aspart injection (Rapilin?), mixed protamine zinc lispro injection (25R) (Prandilin?25), aspart 30 injection (Rapilin?30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin?30). We have two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine?).

     

    In the future, Gan & Lee strives to achieve a comprehensive coverage in the field of diabetes diagnosis and treatment. Moving forward to advance our goal of becoming a world-class pharmaceutical company, we will also take an active part in developing new chemical entities, and work on the treatment of cardiovascular diseases, metabolic diseases, cancer, and other therapeutics. 




    Copyright ? 2021 Gan & Lee Pharmaceuticals. All Rights Reserved. 京ICP備10213074號-1 | 京公網安備 11011202003900號
    Our websites

    Subscribe

    I read, agree with and accept all of the Privacy Policy and Terms of Use of this website.
    主站蜘蛛池模板: 久久综合九色综合欧美就去吻| 无遮挡色视频真人免费| 成人99国产精品| 国产成人高清亚洲一区久久| 人人鲁人人莫人人爱精品| 中文字幕视频一区| 色吊丝av中文字幕| 最新国产午夜精品视频不卡| 国色天香社区高清在线观看| 制服丝袜日韩欧美| 中文字幕在线播放第一页| 成人免费黄网站| 欧美日韩不卡高清| 在镜子里看我怎么c你的| 人人妻人人澡人人爽不卡视频 | 97色伦综合在线欧美视频| 精品精品国产高清a毛片| 日韩人妻无码一区二区三区99| 国产精品亚洲专一区二区三区| 亚洲精品视频在线播放| yellow中文字幕在线高清| 美女扒开尿囗给男生桶爽| 日本三级片网站| 变态调教视频国产九色| 中文字幕无码不卡一区二区三区| 美女免费视频黄的| 无码一区二区三区在线| 国产丰满肥熟在线观看| 久久人人爽人人爽人人片dvd| 色伦专区97中文字幕| 好朋友4韩国完整版观看| 全彩里番acg海贼王同人本子| a级毛片免费高清毛片视频| 男生和女生一起差差差差 | 波多野结衣中文无毒不卡| 夜夜爽一区二区三区精品| 亚洲欧美一区二区三区日产| 91精品一区二区| 日韩精品极品视频在线观看免费| 国产无遮挡又黄又爽免费视频| 亚洲av网址在线观看|